IL17A and psoriasis vulgaris: For patients with moderate to severe plaque psoriasis, biologics that inhibit TNF-α, p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor, have emerged as promising therapies [28].